netFormulary Tameside and Glossop Integrated Care NHS
NHS Foundation Trust  

Useful Links

News Feed
MHRA Drug Safety Update (January 2018): Daclizumab, Erythropoietins, Co-dydramol
MHRA Drug Safety Update (December 2017): Cladribine, Fingolimod, Eluxadoline
MHRA Drug Safety Update (November 2017): Gentamycin, Quinine, Oral Tacrolimus
MHRA Drug Safety Update (October 2017). Methylprednisolone, Gabapentin, Isotretinoin, Clozapine
MHRA Drug Safety Update (September 2017). Miconazole oral gel, loperamide.


This Formulary is intended primarily for use by staff working within Tameside and Glossop Integrated Care NHS Foundation Trust . It is also accessible by General Practitioners , patients and the public at

The on-going development of the formulary is overseen by the Drugs and Therapeutics Committee (DTC) and choices are based on clinical evidence and consultant and GP opinion. The formulary aims to provide information on medicines available at TGH reflecting evidence-based, cost-effective choices and whether their use is considered as good use of NHS resources.

Applications for medicines to be considered for inclusion in the trust formulary must be submitted to the Trust Drugs and Therapeutics Committee. The application form to submit an application is available at http://tis/documents/Medicines_Formulary_Request_Form.pdf

The database is formatted in accordance with British National Formulary chapter classification for ease of use and also includes hyperlinks to the e-BNF, e-BNFc and to the electronic medicines compendium which is a library of Summaries of Product Characteristics (SPCs) and Patient Information Leaflets (PILs).

The formulary will assume that prescribers will use a  drug’s summary of product characteristics (SPC) and the British National Formulary (BNF) to inform decisions made with individual patients (this includes obtaining information on special warnings, precautions for use, contraindications and adverse effects of pharmacological treatments). The formulary should be used in conjunction with clinical judgement and decision-making appropriate for the individual patient.

The formulary recommends some drugs for indications for which they do not have UK marketing authorisation at the date of publication, if there is good evidence to support that use. The prescriber should follow the relevant professional guidance, taking full responsibility for the decision.

Formulary approved medicines are displayed in order of preference and first and second line choices for groups of medicines are indicated if applicable. Where there is no order of preference, medicines appear in alphabetical order. Those medicines which are restricted (by speciality , consultant, indication or clinical area) are also highlighted within the formulary. Although the formulary reflects medicines currently in use at TGH, any medicine approved for use by the National Institute for Health and Care Excellence (NICE) will automatically be approved for use in the Trust if an application to use it is received.

Hyperlinks to relevant National Guidance, such as Drug Safety Updates and guidance issued by NICE, are also included within each section of the formulary. Links to Local Trust Guidelines are also included, however these are presently only available if viewing the formulary on the Trust Intranet. Copies of local guidelines are available on request by using the 'Feedback' link at the top of the page. NICE information is also available at

Searches of the formulary can be undertaken by medicine name, class or medical condition. Some medicines may appear more than once within the formulary. If they are within the same section, this may be because there is more than one brand of the medicine available. However, medicines may also appear in more than one section, as they may be used for more than one medical condition.Some medicines are approved only for prescribing by the hospital, whereas the prescribing for others can be initiated or maintained by local General Practitioners (GPs). A traffic light system highlights these medicines within the formulary.

The Drugs and Therapeutics Committee would be pleased to receive constructive comments on any aspect of the formulary, which can be made by using the 'Feedback' link at the top of the page.

Tony Sivner, Chief Pharmacist

Dr Therese Brammah, Chair, Drugs & Therapeutics Committee

Alison Ahmed, Formulary Pharmacist

Updated February 2017

   Visits = 62273
   Last updated: 21/02/2018 10:24:13